EMA panel grants positive opinion for Remdesivir use in COVID patients with severe renal impairment, including those on dialysis: Gilead Sciences Ruchika Sharma28 May 2023 12:00 PM ISTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Sciences, Arcus Biosciences expand partnership to include research programs in inflammation Ruchika Sharma16 May 2023 10:30 AM ISTFoster City: Gilead Sciences, Inc. and Arcus Biosciences, Inc. have announced that the companies have expanded the previously announced research...
Gilead Sciences acquires all outstanding shares of XinThera Ruchika Sharma13 May 2023 10:00 AM ISTFoster City: Gilead Sciences, Inc. has announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San...
Gilead Sciences gets EMA panel postive opinion recommending full marketing nod of Hepcludex for HDV Ruchika Sharma5 May 2023 1:30 PM ISTFoster City: Gilead Sciences, Inc. has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Gilead Sciences, US square off in billion-dollar HIV drug patent trial Ruchika Sharma2 May 2023 3:46 PM ISTThe USFDA approved Gilead's Truvada for HIV prevention in 2012 and approved its related drug Descovy for the same purpose in 2019.
Lupin Hepatitis B virus drug gets USFDA okay Ruchika Sharma1 April 2023 11:23 AM ISTMumbai: Global pharma major Lupin Limited has announced that the company has received approval from the United States Food and Drug Administration...
Gilead Sciences exercises option to license Nurix's investigational targeted protein degrader molecule NX-0479 Ruchika Sharma21 March 2023 5:22 PM ISTFoster City: Gilead Sciences, Inc. and Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted protein...
Unichem Labs bags USFDA nod for chronic angina drug Ranolazine Extended Release Ruchika Sharma17 March 2023 1:15 PM ISTRanolazine Extended-Release Tablets, 500 mg, and 1000 mg are indicated for the treatment of chronic angina.
Drug companies face COVID cliff in 2023 as sales set to plummet Ruchika Sharma8 Feb 2023 3:27 PM ISTNew York: Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up...
Gilead Sciences secures USFDA okay for Trodelvy for pre-treated HR+/HER2- Metastatic Breast Cancer Ruchika Sharma4 Feb 2023 11:37 AM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
EMA validates marketing authorization application for Trodelvy for Pre-treated HR+/HER2- Metastatic Breast Cancer: Gilead Sciences Ruchika Sharma5 Jan 2023 4:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences to acquire all remaining rights to potential first-in-class immunotherapy GS-1811 from Jounce Therapeutics Ruchika Sharma28 Dec 2022 12:30 PM ISTJounce will receive proceeds of $67 million for this transaction, and Gilead will be solely responsible for all further research, development, and...
